dc.contributor.author | Bassi, Nicola | |
dc.contributor.author | Hovland, Henrikke Nilsen | |
dc.contributor.author | Rasheed, Kashif | |
dc.contributor.author | Ghelue, Marijke van | |
dc.date.accessioned | 2023-09-04T11:32:15Z | |
dc.date.available | 2023-09-04T11:32:15Z | |
dc.date.issued | 2023-04-21 | |
dc.description.abstract | Background - Damaging alterations in the BRCA1 gene have been extensively described as one of the main causes of hereditary breast and ovarian cancer (HBOC). BRCA1 alterations can lead to impaired homologous recombination repair (HRR) of double-stranded DNA breaks, a process which involves the RING, BRCT and coiled-coil domains of the BRCA1 protein. In addition, the BRCA1 protein is involved in transcriptional activation (TA) of several genes through its C-terminal BRCT domain.<p>
<p>Methods - In this study, we have investigated the effect on HRR and TA of 11 rare BRCA1 missense variants classified as variants of uncertain clinical significance (VUS), located within or in close proximity to the BRCT domain, with the aim of generating additional knowledge to guide the correct classification of these variants. The variants were selected from our previous study “BRCA1 Norway”, which is a collection of all BRCA1 variants detected at the four medical genetic departments in Norway.<p>
<p>Results - All variants, except one, showed a significantly reduced HRR activity compared to the wild type (WT) protein. Two of the variants (p.Ala1708Val and p.Trp1718Ser) also exhibited low TA activity similar to the pathogenic controls. The variant p.Trp1718Ser could be reclassified to likely pathogenic. However, for ten of the variants, the total strength of pathogenic evidence was not sufficient for reclassification according to the CanVIG-UK BRCA1/BRCA2 gene-specific guidelines for variant interpretation.<p>
<p>Conclusions - When including the newly achieved functional evidence with other available information, one VUS was reclassified to likely pathogenic. Eight of the investigated variants affected only one of the assessed activities of BRCA1, highlighting the importance of comparing results obtained from several functional assays to better understand the consequences of BRCA1 variants on protein function. This is especially important for multifunctional proteins such as BRCA1. | en_US |
dc.identifier.citation | Bassi N, Hovland HN, Rasheed K, Ghelue Mv. Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays. BMC Cancer. 2023;23(1) | en_US |
dc.identifier.cristinID | FRIDAID 2147339 | |
dc.identifier.doi | 10.1186/s12885-023-10790-w | |
dc.identifier.issn | 1471-2407 | |
dc.identifier.uri | https://hdl.handle.net/10037/30676 | |
dc.language.iso | eng | en_US |
dc.publisher | Springer Nature | en_US |
dc.relation.journal | BMC Cancer | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2023 The Author(s) | en_US |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | en_US |
dc.rights | Attribution 4.0 International (CC BY 4.0) | en_US |
dc.title | Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |